Latest news with #TEVA
Yahoo
21 hours ago
- Business
- Yahoo
Countdown to Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street Forecasts for Key Metrics
Analysts on Wall Street project that Teva Pharmaceutical Industries Ltd. (TEVA) will announce quarterly earnings of $0.63 per share in its forthcoming report, representing an increase of 3.3% year over year. Revenues are projected to reach $4.29 billion, increasing 3% from the same quarter last year. Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe. Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight. With that in mind, let's delve into the average projections of some Teva Pharmaceutical Industries metrics that are commonly tracked and projected by analysts on Wall Street. The average prediction of analysts places 'Revenue- COPAXONE- Total' at $101.85 million. The estimate indicates a change of -31.2% from the prior-year quarter. Analysts expect 'Revenue- API sales to third parties' to come in at $156.49 million. The estimate indicates a change of +3.6% from the prior-year quarter. The consensus among analysts is that 'Revenue- Other- Total' will reach $259.03 million. The estimate indicates a change of +144.4% from the prior-year quarter. The collective assessment of analysts points to an estimated 'Geographic Revenue- Europe' of $1.25 billion. The estimate points to a change of +3.3% from the year-ago quarter. Analysts' assessment points toward 'Geographic Revenue- International Markets' reaching $602.40 million. The estimate points to a change of +1.6% from the year-ago quarter. The combined assessment of analysts suggests that 'Geographic Revenue- United States' will likely reach $2.19 billion. The estimate suggests a change of +3.6% year over year. It is projected by analysts that the 'Geographic Revenue- United States- Anda' will reach $358.28 million. The estimate indicates a change of -4% from the prior-year quarter. Analysts predict that the 'Geographic Revenue- Europe- COPAXONE' will reach $40.50 million. The estimate points to a change of -23.6% from the year-ago quarter. Analysts forecast 'Geographic Revenue- Europe- Respiratory products' to reach $55.07 million. The estimate points to a change of -3.4% from the year-ago quarter. Based on the collective assessment of analysts, 'Geographic Revenue- International Markets- Generic products' should arrive at $478.57 million. The estimate indicates a year-over-year change of -1.5%. According to the collective judgment of analysts, 'Geographic Revenue- International Markets- COPAXONE' should come in at $10.83 million. The estimate indicates a change of -22.7% from the prior-year quarter. The consensus estimate for 'Geographic Revenue- United States- AJOVY' stands at $50.80 million. The estimate points to a change of +21% from the year-ago quarter. View all Key Company Metrics for Teva Pharmaceutical Industries here>>> Shares of Teva Pharmaceutical Industries have demonstrated returns of -1.3% over the past month compared to the Zacks S&P 500 composite's +4.9% change. With a Zacks Rank #3 (Hold), TEVA is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
Teva Pharmaceutical (TEVA) Just Flashed a Statistically Viable Signal for Bullish Traders
Bold speculators interested in a quick strike may want to set their sights on healthcare specialist Teva Pharmaceutical Industries (TEVA). But rather than a long discussion on fundamental items that are essentially summaries of yesterday's newspaper, I'd like to begin the discussion about TEVA stock with a thought experiment. Imagine that you flip a (fair) coin 100 times every business day. What you flip on Monday would have no bearing on what you flip on Tuesday and so forth. Obviously, coin tosses represent random events. If your job was to determine the likelihood of a higher ratio of heads versus tails on Friday, knowing what the 'score' was on the previous day would offer no useful intelligence. Delta Air Lines Shows Unusual Call Options Ahead of Earnings - Investors are Bullish on DAL Stock Covered Call Screener Results For July 9th Creating a 38% 'Dividend' on SOFI Stock Using Options Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Now imagine that the stock market is random. If investors were net buyers of a security on Monday, this fact would have no bearing on the stock's performance on Tuesday. It would also mean that analysts could pull up historical price data and check the performance of the security across multiple time intervals. In a random ecosystem, the long-side success ratio for all these intervals would hover around 50%. Instinctively, we understand that this null hypothesis isn't valid: otherwise, why bother with the financial publication industry? The point of this sector is to decipher the statistical landscape of the security at hand and act only when the odds favor the speculator. Over the past few months, I've personally drifted away from fundamental and technical analysis, in large part because these methodologies seek to extract forward probabilities based on vibes and stuff. Instead, we should extract the probabilities using math. Applying statistical analysis on a publicly traded enterprise is conceptually a difficult concept because of the non-stationary problem. Essentially, the share price rarely stays localized in a narrow range. Instead, it moves, often wildly. For example, TEVA stock has more than doubled in value since late October 2023. This makes probabilistic analysis based on the use of past analogs rather challenging. To get around this problem, we can apply discretization; that is, convert price action into discrete events. For this purpose, market breadth — or sequences of accumulative and distributive sessions — represents a viable solution. As a representation of demand, market breadth is effectively binary as investors are either net buyers or net sellers during a particular session. From here, individual market profiles can be segregated into distinct behavioral states. If we convert TEVA stock's historical price data (across 10-week intervals) since January 2019 into market breadth, we get the below summation: Ticker L10 Category Sample Size Up Probability Baseline Probability Delta Median Return if Up TEVA 1-9-D 9 44.44% 49.71% -5.27% 7.66% TEVA 2-8-D 10 10.00% 49.71% -39.71% 3.05% TEVA 3-7-D 13 69.23% 49.71% 19.52% 3.34% TEVA 3-7-U 1 0.00% 49.71% -49.71% N/A TEVA 4-6-D 51 60.78% 49.71% 11.07% 4.70% TEVA 4-6-U 19 52.63% 49.71% 2.92% 3.94% TEVA 5-5-D 46 39.13% 49.71% -10.58% 2.62% TEVA 5-5-U 38 52.63% 49.71% 2.92% 4.22% TEVA 6-4-D 13 53.85% 49.71% 4.14% 3.21% TEVA 6-4-U 50 48.00% 49.71% -1.71% 3.52% TEVA 7-3-D 3 100.00% 49.71% 50.29% 8.55% TEVA 7-3-U 21 47.62% 49.71% -2.09% 2.09% TEVA 8-2-U 16 56.25% 49.71% 6.54% 1.77% TEVA 9-1-U 6 50.00% 49.71% 0.29% 4.24% Currently, TEVA stock is printing a 4-6-D sequence: four up weeks, six down weeks, with a negative trajectory across the 10-week period. What's significant about this sequence is that, in 60.78% of cases, the following week's price action results in upside, with a median return of 4.7%. While this statistical profile doesn't guarantee upside success, what it does is establish guideposts to help the decision-making process. Traders may thus treat TEVA stock like a game of blackjack. Certain hands or sequences aren't favorable to the bullish speculator so they may hold off. However, the 4-6-D sequence is statistically favorable, making a debit-based wager enticing. Also, if the market were truly random, all these sequences would share roughly the same probability — around 50%. They don't. Some sequences clearly favor long-side speculation, which is why TEVA stock is tempting. Using the market intelligence above, speculators who want to roll the dice may consider the 17/17.50 bull call spread expiring July 18. This transaction involves buying the $17 call and simultaneously selling the $17.50 call, for a net debit paid of $15 (the most that can be lost in the trade). Should TEVA stock rise through the short strike price ($17.50) at expiration, the maximum reward is $35 or a payout of over 233%. Admittedly, this is a tight time window. For those who want an extra week, they may consider the 16.50/18 bull spread expiring July 25. However, the short strike price jumps from $17.50 to $18, which is almost a 3% difference. That's something to keep in mind because it's quite a steep price in exchange for the time cushion. Either way, the probabilistic principle undergirding the above trades is this: as a baseline, TEVA stock has a slightly negative bias so the 4-6-U sequence incentivizes a bullish posture. Specifically, a random long position has a 49.56% chance of being profitable over a one-week period. However, the aforementioned sequence tilts the odds in favor of the bull, thus warranting consideration. On the date of publication, Josh Enomoto did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Business
- Yahoo
Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the most promising stocks according to Wall Street analysts. On June 16, Teva Pharmaceutical announced a collaboration agreement with China-based Shanghai Fosun Pharmaceutical Group Co., Ltd. (better known as Fosun Pharma) to co-develop TEV-56278, which is an investigational anti-PD1-IL2 ATTENUKINE therapy. The partnership will accelerate clinical data generation for TEV-56278, which is currently in a Phase 1 study for various forms of cancer, such as melanoma. TEV-56278 is an internally developed Teva product and is an anti-PD-1 antibody-cytokine fusion protein that uses Teva's proprietary ATTENUKINE technology. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Its novel mechanism of action is designed to selectively deliver interleukin-2 (IL-2) to PD-1-expressing T cells within the tumor microenvironment. Under the terms of the agreement, Fosun Pharma has been granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in mainland China, the Hong Kong SAR, Macau SAR, Taiwan region, and select Southeast Asian countries. Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, manufactures, markets, and distributes generic & other medicines and biopharmaceutical products internationally. Fosun Pharma is a global healthcare company in pharmaceuticals, medical devices & diagnostics, and healthcare services. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
25-06-2025
- Business
- Yahoo
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit Cautionary Note Regarding Forward-Looking StatementsThis press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors'. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Teva Media Inquiries Teva Investor Relations InquiresError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-06-2025
- Business
- Yahoo
Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Goldman Sachs analysts began coverage of Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $24, on June 6. The analysts' optimistic view was driven in part by a strengthening core business and growth possibilities in the branded segment. According to the analysts, Teva's branded segment, which includes medications like Austedo, Uzedy, Ajovy, and LAI olanzapine, has significant growth potential. They estimate that these assets will generate substantial growth in fiscal year 2027, around 10% higher than the mainstream projections. This optimism stems from recent script data and commercial investments, including direct-to-consumer marketing. On the other hand, Goldman Sachs analysts see modest growth in the generics sector over the upcoming years. Although Teva's growing portfolio of biosimilars—five more are anticipated to be introduced in the United States between fiscal years 2025 and 2027—offers potential, the gRevlimid settlement's expiration in 2026 may offset this growth. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a multinational pharmaceutical company based in Israel. Although generic medications are Teva's primary area of expertise, the company also has branded drug assets. While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
